COMMUNIQUÉS West-GlobeNewswire

New Analysis of Over 50 Studies Showed that All the Non-Prescription CBD Products Researched Fell Short of Therapeutic Efficacy — Reinforcing the Case for Artelo's Optimized ART12.11 CBD Composition
22/07/2026
Review Article Now Published in the British Journal of Clinical Pharmacology Finds Widely Sold Non-Prescription CBD Products at Doses Administered Failed to Provide Adequate Exposure for Positive Biological Effect [...]
Guidelight Health Opens Eighth Massachusetts Location, Expanding Access to Structured Mental Health Care
22/07/2026
New Andover location and statewide virtual IOP extend timely, evidence-based care across the Commonwealth ANDOVER, Mass., July 22, 2026 (GLOBE NEWSWIRE) -- Guidelight Health, a leader in evidence-based mental health [...]
Specialized Manufacturing Capability Emerges as the New Competitive Advantage in the $23.2 Billion Global Biologics CDMO Market, Finds Alira Health
22/07/2026
Annual report examines how specialized manufacturing capabilities, investment, and M&A are reshaping the global biologics contract manufacturing landscape FRAMINGHAM, Mass., July 22, 2026 (GLOBE NEWSWIRE) -- Alira [...]
Monopar Initiates Rolling NDA Submission for ALXN1840 in Wilson Disease
22/07/2026
WILMETTE, Ill., July 22, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with [...]
Radiopharm Theranostics Achieves Confirmed Durable Partial Response in Ongoing Phase 1 Trial of RAD204 in Patients with Advanced Solid Tumors Post-Immunotherapy
22/07/2026
First RECIST-confirmed durable Partial Response at current highest dose level #3 (90mCi) with the patient remaining progression free beyond seven months Second patient dosed remains progression free on treatment with [...]
Healx Announces First Patient Dosed in Phase 1/2 Trial to Evaluate the Effect of HLX-4310 on Metastatic Recurrence and Progression in Sarcomas with a Focus on Osteosarcoma
22/07/2026
Cambridge, UK – 22 July, 2026 – Healx, an AI-powered, clinical-stage biotech company dedicated to rare diseases, today announced that the first patient has been dosed in its Phase 1/2 dose-escalation and dose- [...]
Biodesix to Report Second Quarter 2026 Financial Results on August 5, 2026
22/07/2026
LOUISVILLE, Colo., July 22, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced that it will release financial results for the second quarter ended June 30, [...]
Genenta-Backed Sòphia High Tech Reports Fiscal Year 2025 Results
22/07/2026
Sales rise 29.3% and EBITDA grows 68.1%; newly appointed Board of Directors to lead the next phase of aerospace and defense growth Fiscal Year 2025 Highlights FY2025 sales rose 29.3% to €7.17 million; total value of [...]
Repligen to Acquire BioLife Solutions, Expanding Its Cell Therapy Capabilities with Market Leading Biopreservation Media
22/07/2026
Fast-tracks Repligen’s leadership and customer solution offering in high-growth cell therapy market by adding BioLife’s differentiated, high-margin recurring revenue business BioLife stockholders to receive cash and [...]
RadNet, Inc. Announces Date of its Second Quarter 2026 Financial Results Conference Call
22/07/2026
LOS ANGELES, July 22, 2026 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT) , a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of owned and operated outpatient [...]
Acentra Health Appoints Sreedevi Hegde as Senior Vice President – India Country Head
22/07/2026
Seasoned global business leader to drive the growth of Acentra Health's India organization and accelerate the company's transformation journey MCLEAN, Va., July 22, 2026 (GLOBE NEWSWIRE) -- Acentra Health , a technology [...]
Geron Plans to Announce Second Quarter 2026 Financial Results on August 5, 2026
22/07/2026
FOSTER CITY, Calif., July 22, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that [...]
BioCryst to Report Second Quarter 2026 Financial Results on August 5
22/07/2026
RESEARCH TRIANGLE PARK, N.C., July 22, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its second quarter 2026 financial results on Wednesday, August 5 [...]
Avalo Therapeutics to Participate in the BTIG Biotechnology Conference
22/07/2026
WAYNE, Pa., July 22, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing therapeutics targeting the IL-1β pathway for immune-mediated [...]
Standard BioTools to Announce Second Quarter 2026 Financial Results on August 5, 2026
22/07/2026
BOSTON, Mass., July 22, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced that it will publish its second quarter 2026 financial results on Wednesday, August 5, 2026, after U.S. market close [...]
Publication in Clinical Reviews in Allergy & Immunology Summarizes Decades of Evidence Supporting Bradykinin B2 Receptor as a Validated Therapeutic Target in Bradykinin-Mediated Angioedema
22/07/2026
Provides a state-of-the-art overview of the evidence on the critical role of bradykinin B2 receptor in the pathogenesis of bradykinin-mediated angioedema Explains the scientific foundation for targeting the bradykinin [...]
Greenwich LifeSciences Announces Approval to Expand FLAMINGO-01 into the United Kingdom
22/07/2026
STAFFORD, Texas, July 22, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is [...]
Vivoryon Therapeutics N.V. to Report H1 2026 Financial Results and Business Updates on August 6, 2026; Annual General Meeting Planned for End of September 2026
22/07/2026
Vivoryon Therapeutics N.V. to Report H1 2026 Financial Results and Business Updates on August 6, 2026; Annual General Meeting Planned for End of September 2026 Halle (Saale) / Munich, Germany, July 22 , 2026 - Vivoryon [...]
Ipsen completes acquisition of Memo Therapeutics AG, adding first-in-class asset to Ipsen's Rare Disease pipeline
22/07/2026
PARIS, FRANCE, 22 JULY 2026 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today it has completed the acquisition of Memo Therapeutics AG, a late-stage biotech company focused on potravitug, an anti-BK polyomavirus [...]

Pages